Hydrophobicity causes anomalous migration of cystine/glutamate antiporter SLC7A11 in SDS-PAGE with low acrylamide concentration

被引:0
|
作者
Emmanuel, Nsengiyumva [1 ,2 ]
He, Qian [1 ]
Kang, Yixin [3 ]
Zhang, Dianbao [3 ]
Gao, Min [1 ]
Wang, Minglin [1 ]
Fan, Kexin [1 ]
Xiong, Jingwen [1 ]
Wu, Shaobo [1 ]
Fa, Botao [1 ]
Xiao, Zhengtao [1 ]
Niu, Yingfang [4 ]
Yao, Jun [3 ]
Zhang, Yilei [1 ]
机构
[1] Xi An Jiao Tong Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Xian 710061, Shaanxi, Peoples R China
[2] Univ Rwanda, Coll Med & Hlth Sci, Sch Hlth Sci, Dept Biomed Lab Sci, Kigali, Rwanda
[3] Henan Univ Sci & Technol, Affiliated Hosp 1, Canc Inst, Coll Clin Med,Henan Key Lab Canc Epigenet, Luoyang 471003, Peoples R China
[4] Shenzhen Polytech Univ, Guangdong Hong Kong Macao Greater Bay Area Cultura, Sch Management, Hong Kong, Peoples R China
来源
FEBS OPEN BIO | 2025年
基金
中国国家自然科学基金;
关键词
acrylamide gel concentration; gel mobility; hydrophobicity; SDS-PAGE; transmembrane domain; MEMBRANE-PROTEIN; XCT; ELECTROPHORESIS; FERROPTOSIS; MECHANISMS; MOBILITY; BEHAVIOR;
D O I
10.1002/2211-5463.70019
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The cystine/glutamate antiporter, solute carrier family 7 member 11 (SLC7A11), plays a crucial role in regulating redox homeostasis and cell death processes such as apoptosis and ferroptosis. These processes are implicated in various diseases, including cancer, organ injuries and neurodegenerative disorders. However, the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) expression pattern of SLC7A11 varies across studies and remains unclear. In many studies, including ours, SLC7A11 migrates at an atypical molecular weight (MW) of approximately 37 kDa, which is lower than its theoretical molecular mass of 55.4 kDa. This discrepancy raises concerns about the precise molecular mass and expression pattern of SLC7A11 in SDS-PAGE. We confirmed that this fast-migrating band corresponds to SLC7A11 through knockdown of endogenous SLC7A11 or overexpression of exogenous SLC7A11. Furthermore, we ruled out the possibility of proteolytic cleavage after protein translation. We found that the high hydrophobicity of SLC7A11 is a key factor responsible for its anomalous migration. Substituting the non-polar residue isoleucine (Ile) with the polar residue asparagine (Asn) reduced its hydrophobicity and restored normal migration, aligning with its predicted MW of 55 kDa. Additionally, we observed that SLC7A11 migrated faster in SDS-PAGE at lower acrylamide concentrations, whereas higher concentrations (e.g. 12% or 15%) eliminated the gel shift. This study clarifies the expression pattern of SLC7A11 in SDS-PAGE and emphasizes the importance of considering physicochemical properties such as hydrophobicity and gel concentration when characterizing membrane proteins like SLC7A11.
引用
收藏
页数:15
相关论文
共 32 条
  • [1] The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer
    Jyotsana, Nidhi
    Ta, Kenny T.
    DelGiorno, Kathleen E.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [2] The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate
    Koppula, Pranavi
    Zhang, Yilei
    Shi, Jiejun
    Li, Wei
    Gan, Boyi
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2017, 292 (34) : 14240 - 14249
  • [3] Analysis of DNA methylation associates the cystine–glutamate antiporter SLC7A11 with risk of Parkinson’s disease
    Costanza L. Vallerga
    Futao Zhang
    Javed Fowdar
    Allan F. McRae
    Ting Qi
    Marta F. Nabais
    Qian Zhang
    Irfahan Kassam
    Anjali K. Henders
    Leanne Wallace
    Grant Montgomery
    Yu-Hsuan Chuang
    Steve Horvath
    Beate Ritz
    Glenda Halliday
    Ian Hickie
    John B. Kwok
    John Pearson
    Toni Pitcher
    Martin Kennedy
    Steven R. Bentley
    Peter A. Silburn
    Jian Yang
    Naomi R. Wray
    Simon J. G. Lewis
    Tim Anderson
    John Dalrymple-Alford
    George D. Mellick
    Peter M. Visscher
    Jacob Gratten
    Nature Communications, 11
  • [4] Analysis of the cystine/glutamate antiporter xCT (SLC7A11) as a biomarker in several tumor types using immunohistochemistry
    Rojas, A.
    Salameh, A.
    Blezinger, P.
    Caldeira, J.
    Perrine, M.
    Patti, J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S27 - S27
  • [5] Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson's disease
    Vallerga, Costanza L.
    Zhang, Futao
    Fowdar, Javed
    McRae, Allan F.
    Qi, Ting
    Nabais, Marta F.
    Zhang, Qian
    Kassam, Irfahan
    Henders, Anjali K.
    Wallace, Leanne
    Montgomery, Grant
    Chuang, Yu-Hsuan
    Horvath, Steve
    Ritz, Beate
    Halliday, Glenda
    Hickie, Ian
    Kwok, John B.
    Pearson, John
    Pitcher, Toni
    Kennedy, Martin
    Bentley, Steven R.
    Silburn, Peter A.
    Yang, Jian
    Wray, Naomi R.
    Lewis, Simon J. G.
    Anderson, Tim
    Dalrymple-Alford, John
    Mellick, George D.
    Visscher, Peter M.
    Gratten, Jacob
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [6] Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance
    Lim, Jonathan K. M.
    Delaidelli, Alberto
    Minaker, Sean W.
    Zhang, Hai-Feng
    Colovic, Milena
    Yang, Hua
    Negri, Gian Luca
    von Karstedt, Silvia
    Lockwood, William W.
    Schaffer, Paul
    Leprivier, Gabriel
    Sorensen, Poul H.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (19) : 9433 - 9442
  • [7] High expression of cystine–glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma
    Mai Froberg Sørensen
    Sólborg Berglind Heimisdóttir
    Mia Dahl Sørensen
    Casper Schau Mellegaard
    Helle Wohlleben
    Bjarne Winther Kristensen
    Christoph Patrick Beier
    Journal of Neuro-Oncology, 2018, 138 : 49 - 53
  • [8] The clinical significance of glutamate/cystine antiporter SLC7A11/xCT in non-small cell lung cancer
    Liu, Dage
    Nakashima, Nariyasu
    Nakano, Takayuki
    Zhang, Xia
    Yokomise, Hiroyasu
    CANCER SCIENCE, 2018, 109 : 1425 - 1425
  • [9] Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance
    Huang, Y
    Dai, ZY
    Barbacioru, C
    Sadée, W
    CANCER RESEARCH, 2005, 65 (16) : 7446 - 7454
  • [10] HIGH EXPRESSION OF CYSTINE-GLUTAMATE ANTIPORTER XCT (SLC7A11) IS AN INDEPENDENT BIOMARKER FOR EPILEPTIC SEIZURES AT DIAGNOSIS IN GLIOMA
    Beier, C. P.
    Heimisdottir, S. B.
    Soerensen, M. F.
    Wohlleben, H.
    Kristensen, B. W.
    EPILEPSIA, 2017, 58 : S24 - S24